TipRanks
Time to Load up on Atossa Shares? This Analyst Thinks So
The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché…) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock. Since the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer tre
